Announcements Trials
Browse Landscape

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

Blood Specimen Collection 27Surveys and Questionnaires 24Magnetic Resonance Spectroscopy 10Observation 7Flow Cytometry 7Specimen Handling 6Amplified Fragment Length Polymorphism Analysis 6exemestane 5Radiotherapy 5Magnetic Resonance Imaging 5Immunoenzyme Techniques 5Biopsy 5Radiation 4Neoadjuvant Therapy 4Mental Status and Dementia Tests 4Genetic Testing 4Gene Expression Profiling 4Electroporation 4Data Collection 4Bevacizumab 4Trastuzumab 3Tomography, X-Ray Computed 3Tomography, Optical Coherence 3Therapeutics 3Surgical Procedures, Operative 3Sunitinib 3Sorafenib 3Registries 3Radiosurgery 3Psychiatric Rehabilitation 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Observational × erdafitinib × Clear all
NCT05052372 2022-12-22

Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib

xCures

Terminated
2 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡